Literature DB >> 8993963

Acute generalized exanthematous pustulosis induced by paracetamol. A case with severe hemodynamic disturbances.

A L De Coninck1, A S Van Strubarq, M A Pipeleers-Marichal, L P Huyghens, E T Suys, D I Roseeuw.   

Abstract

We report on a 28-year-old Bangladesh man with acute generalized exanthematous pustulosis, induced by paracetamol. The patient presented with an erythematous and pustular eruption after taking 1 tablet of paracetamol for a sore throat. After intravenous administration of propacetamol hydrochloride (which is a prodrug of paracetamol), the rash became worse, showing a toxic epidermal necrolysis-like appearance and the patient suffered from severe hemodynamic disturbances. After discontinuation of propacetamol hydrochloride, the eruption cleared within 2 days. Prick testing performed in the patient revealed a positive reaction for propacetamol hydrochloride.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8993963     DOI: 10.1159/000246286

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

1.  Acute generalized exanthematous pustulosis with severe organ dysfunction.

Authors:  Marc-André Leclair; Bruno Maynard; Catherine St-Pierre
Journal:  CMAJ       Date:  2009-07-20       Impact factor: 8.262

2.  Clinical characteristics and management of acute generalized exanthematous pustulosis with haemodynamic instability.

Authors:  M O'Brian; C L Carr; C Thomas; A R Dominguez; M Mauskar
Journal:  Skin Health Dis       Date:  2021-11-15

3.  Acute Generalized Exanthematous Pustulosis following SARS-CoV-2 Virus: Remdesivir as a Suspected Culprit.

Authors:  Fatemeh Mohaghegh; Parvaneh Hatami; Zeinab Aryanian; Farahnaz Fatemi; Zeinab Mohseni Afshar
Journal:  Case Rep Med       Date:  2022-08-10

4.  Acute generalized exanthematous pustulosis simulating toxic epidermal necrolysis: case presentation and literature review.

Authors:  Ana-Maria Copaescu; Danielle Bouffard; Marie-Soleil Masse
Journal:  Allergy Asthma Clin Immunol       Date:  2020-02-04       Impact factor: 3.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.